CHMP recommends EU approval of Roche’s Alecensa (alectinib) for ALK-positive NSCLC
Roche announced the EU Committee for Medicinal Products for Human Use has adopted a positive opinion recommending the approval of Alecensa® (alectinib) as a monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase-positive, advanced non-small cell lung cancer. October 13, 2017